Precigen announces first patient dosed in phase 1 clinical study of INXN-4001
Precigen, an Intrexon subsidiary, announced the treatment of the first patient in a Phase 1 first-in-human clinical trial of its investigational therapy, INXN-4001. INXN-4001 is a non-viral, multigene plasmid designed to express three different human proteins. May 21, 2018